<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144204</url>
  </required_header>
  <id_info>
    <org_study_id>2018-07-023B</org_study_id>
    <nct_id>NCT05144204</nct_id>
  </id_info>
  <brief_title>Evaluation of Treatment Effect of Low FODMAP Diet in Treatment of IBS Patients</brief_title>
  <official_title>Evaluation of Treatment Effect and Mechanism of Low FODMAP Diet in Treatment of Irritable Bowel Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder, affecting&#xD;
      15% of the population. IBS is characterized by recurrent abdominal pain/discomfort without&#xD;
      identifiable organic lesions. The pathophysiology of IBS can be multi factors which included&#xD;
      immune activation/inflammatory reactions, visceral hypersensitivity, gastrointestinal&#xD;
      dysmotility, changes in gut microflora, brain-gut dysfunction and food intolerance. Many&#xD;
      short-chain carbohydrates can induce abdominal symptoms, and these carbohydrates were called,&#xD;
      Fermentable, Oligosaccharides, Disaccharides and Monosaccharides and Polyols (FODMAPs).&#xD;
      Around 50- 86% of the IBS patients will have a clinically meaningful response to the&#xD;
      low-FODMAP diet. To evaluate the efficacy of low FODMAP diet. Experimental design: Health&#xD;
      control and patients meeting the ROME III criteria for IBS will be enrolled in this study.&#xD;
      The basic profiles, patient characteristics, intestinal microbiota profiles and MRI images&#xD;
      will be obtained before and after low FODMAP diet intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>irritable bowel syndrome Severity Scale (IBS-SS)</measure>
    <time_frame>Baseline, end of study approximately 6 to 8 weeks ]</time_frame>
    <description>The primary endpoint is the variable used to assess the main objective, the efficacy of low FODMAP diet on gastrointestinal symptoms in IBS (focusing on the elimination phase) change from baseline after 6-8 weeks. The variables used will be the symptom scores of several symptom questionnaires. Ultimately, the efficacy of the diet is based on improvement of symptom scores. Improvement is defined as a 50-point drop on the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). In this questionnaire, each quesiton is scored from 0-100, with a maximum total score of 500. Patients reporting scores &lt;50 are defined as non-IBS individuals, a score from 50-175 indicated mild disease, 175-300 moderate and &gt;300 severe.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Irritable Bowel Syndrome Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low FODMAP diet</intervention_name>
    <description>Low FODMAP diet instruction to irritable bowel syndrome patients.</description>
    <arm_group_label>Irritable Bowel Syndrome Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients are eligible for the study if all of the following criteria are met:&#xD;
&#xD;
          1. Patients with irritable bowel syndrome as per Rome IV diagnostic criteria Symptom&#xD;
             characteristics of IBS according to Rome III and IV criteria&#xD;
&#xD;
          2. Patients must provide witnessed written informed consent prior to any study procedures&#xD;
             being performed&#xD;
&#xD;
          3. Patients aged between 20-65 years&#xD;
&#xD;
          4. Male or female patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria including:&#xD;
&#xD;
               1. Unable to provide or understand written informed consent.&#xD;
&#xD;
               2. Pregnancy.&#xD;
&#xD;
               3. Receiving antibiotics or narcotics within 90 days prior to enrollment.&#xD;
&#xD;
               4. Receiving new prebiotics, probiotics within 90 days prior to enrollment.&#xD;
&#xD;
               5. Current infection.&#xD;
&#xD;
               6. History of inflammatory bowel disease.&#xD;
&#xD;
               7. Thyroid disease.&#xD;
&#xD;
               8. Major psychiatric disorders, including clinical anxiety or depression and&#xD;
                  previous use of anxiolytics and antidepressants.&#xD;
&#xD;
               9. Previous stroke, intracerebral hemorrhage, or central nervous system diseases.&#xD;
&#xD;
              10. Malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ching-Liang Lu</last_name>
    <phone>886228712121</phone>
    <email>cllu@vghtpe.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Po-Shan Wu</last_name>
    <phone>886228712121</phone>
    <email>pswu2@vghtpe.gov.tw</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low FODMAP diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

